Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Joins with iRhythm in Wireless Cardiac Monitoring

This article was originally published in Start Up

Executive Summary

iRhythm Technologies, which has been quietly working on a new platform in arrhythmia monitoring since 2006, came forward with much éclat at the 2010 Heart Rhythm Society Meeting in May. There the company made a two-part announcement: the signing of a co-marketing agreement with St. Jude Medical Inc. and a $10 million Series B round led by St. Jude, with the participation of existing investors Mohr Davidow Ventures, Synergy Life Science Partners, and two additional undisclosed investors. The co-marketing agreement provides validation for the young company operating in a new field, and for its established big partner, a way to use a new diagnostic technology to assure more efficient use of its therapeutic equipment by the health care system.

You may also be interested in...



Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2010

Highlights from the Q1 2010 review of medical device and in vitro diagnostics/research dealmaking: With most of the funding in the form of venture rounds, medical device financing totaled $548 million in the second quarter, a 10% drop from Q1. Device acquisitions picked up, with 18 transactions completed for an aggregate $4.4 billion. Including GenMark's IPO, the first done in the sector since November 2007, in vitro diagnostic/research financing more than doubled Q1's dollar volume, reaching $364 million in the second quarter. The four IVD/Research acquisitions done in Q2 totalled $226 million.

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2010

Highlights from the Q1 2010 review of medical device and in vitro diagnostics/research dealmaking: With most of the funding in the form of venture rounds, medical device financing totaled $548 million in the second quarter, a 10% drop from Q1. Device acquisitions picked up, with 18 transactions completed for an aggregate $4.4 billion. Including GenMark's IPO, the first done in the sector since November 2007, in vitro diagnostic/research financing more than doubled Q1's dollar volume, reaching $364 million in the second quarter. The four IVD/Research acquisitions done in Q2 totalled $226 million.

AF Ablation: Finding the Right Mix

For a number of reasons, 2009 was a big year for the atrial fibrillation ablation market. Early in the year, Biosense Webster received FDA approval for its radiofrequency ablation catheter, the first such device to launch in the US with a specific AF indication. That approval was much more than just a landmark event for J&J; it changed the landscape of the AF industry, reinvigorating interest in the funding and development of new catheter-based technologies--a trend that has extended through to 2010 and will likely continue in the years ahead.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037678

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel